26171-23-3

中文名称托麦汀

英文名称 Tolmetin

CAS 26171-23-3

分子式 C15H15NO3

MDL 编号 MFCD00599595

分子量 257.29

MOL 文件 26171-23-3.mol

更新日期 2024/04/22 14:21:56

26171-23-3 结构式

基本信息物理化学性质安全数据常见问题列表

基本信息

中文别名

甲苯酰吡咯乙酸
痛灭定
托麦汀
托美汀
2-[1-甲基-5-(4-甲基苯甲酰)吡咯-2-基]乙酸

英文别名

Tolmetin
Tolmetine
TOLMETINUM
2-[1-Methyl-5-(4-methylbenzoyl)-pyrrol-2-yl]acetic acid
1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-
1-Methyl-5-p-toluoylpyrrole-2-acetic acid
5-[(p-Tolyl)carbonyl]-1-methylpyrrole-2-acetic acid
McN 2559
1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid
1-Methyl-5-(p-toluoyl)-1H-pyrrole-2-acetic acid

所属类别

生物化工：激动剂抑制剂

物理化学性质

熔点156 °C

沸点400.53°C (rough estimate)

密度1.1391 (rough estimate)

折射率1.5200 (estimate)

储存条件Sealed in dry,2-8°C

溶解度可溶于氯仿（少许）、甲醇（少许）

酸度系数(pKa)pKa 3.5(H2O t undefined I undefined) (Uncertain)

形态固体

颜色灰白色至淡黄色

水溶解性222 mg/L

NIST化学物质信息Tolmetin(26171-23-3)

EPA化学物质信息1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- (26171-23-3)

安全数据

危险性符号(GHS)

GHS07

警示词警告

危险性描述H315-H302-H335-H319

防范说明P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501

毒害物质数据26171-23-3(Hazardous Substances Data)

常见问题列表

生物活性

Tolmetin (Tolectin) 是一种非类固醇的抗炎药，属于杂环乙酸衍生物类，具有止痛和退热作用。

靶点

Human COX-1

0.35 μM (IC ₅₀ )

Human COX-2

0.82 μM (IC ₅₀ )

体外研究

Tolmetin (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat.
Tolmetin (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner.
Tolmetin (0-100 μM) shows no effect on osteoblast growth.

体内研究

Tolmetin (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg.
Tolmetin (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity.